CAPTRUST Financial Advisors
CMMB

CAPTRUST Financial Advisors’s Chemomab Therapeutics CMMB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49
Closed -$1K – 2429
2022
Q2 		$1K Hold
49
– – ﹤0.01% 4649
2022
Q1 		$1K Buy
+49
New +$966 ﹤0.01% 4668

Other funds holding CMMB

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CAPTRUST Financial Advisors's CMMB Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Chemomab Therapeutics (CMMB) in Q3 2022, closing a stake of 49 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in CMMB in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q2 2022. 15 funds tracked by Wall St. Rank hold CMMB as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Chemomab Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 49 Chemomab Therapeutics shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Chemomab Therapeutics in Q1 2022 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Chemomab Therapeutics position peaked at $1K in Q2 2022.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.